Cargando…
Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19
SARS-CoV-2 spike (S) variants that may evade antibody-mediated immunity are emerging. Evidence shows that vaccines with a stronger immune response are still effective against mutant strains. Here, we report a targeted type 1 conventional dendritic (cDC1) cell strategy for improved COVID-19 vaccine d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951015/ https://www.ncbi.nlm.nih.gov/pubmed/35335039 http://dx.doi.org/10.3390/vaccines10030407 |
_version_ | 1784675281976426496 |
---|---|
author | Qi, Hailong Sun, Zhongjie Yao, Yanling Chen, Ligong Su, Xuncheng |
author_facet | Qi, Hailong Sun, Zhongjie Yao, Yanling Chen, Ligong Su, Xuncheng |
author_sort | Qi, Hailong |
collection | PubMed |
description | SARS-CoV-2 spike (S) variants that may evade antibody-mediated immunity are emerging. Evidence shows that vaccines with a stronger immune response are still effective against mutant strains. Here, we report a targeted type 1 conventional dendritic (cDC1) cell strategy for improved COVID-19 vaccine design. cDC1 cells specifically express X-C motif chemokine receptor 1 (Xcr1), the only receptor for chemokine Xcl1. We fused the S gene sequence with the Xcl1 gene to deliver the expressed S protein to cDC1 cells. Immunization with a plasmid encoding the S protein fused to Xcl1 showed stronger induction of antibody and antigen-specific T cell immune responses than immunization with the S plasmid alone in mice. The fusion gene-induced antibody also displayed more powerful SARS-CoV-2 wild-type virus and pseudovirus neutralizing activity. Xcl1 also increased long-lived antibody-secreting plasma cells in bone marrow. These preliminary results indicate that Xcl1 serves as a molecular adjuvant for the SARS-CoV-2 vaccine and that our Xcl1-S fusion DNA vaccine is a potential COVID-19 vaccine candidate for use in further translational studies. |
format | Online Article Text |
id | pubmed-8951015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89510152022-03-26 Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 Qi, Hailong Sun, Zhongjie Yao, Yanling Chen, Ligong Su, Xuncheng Vaccines (Basel) Article SARS-CoV-2 spike (S) variants that may evade antibody-mediated immunity are emerging. Evidence shows that vaccines with a stronger immune response are still effective against mutant strains. Here, we report a targeted type 1 conventional dendritic (cDC1) cell strategy for improved COVID-19 vaccine design. cDC1 cells specifically express X-C motif chemokine receptor 1 (Xcr1), the only receptor for chemokine Xcl1. We fused the S gene sequence with the Xcl1 gene to deliver the expressed S protein to cDC1 cells. Immunization with a plasmid encoding the S protein fused to Xcl1 showed stronger induction of antibody and antigen-specific T cell immune responses than immunization with the S plasmid alone in mice. The fusion gene-induced antibody also displayed more powerful SARS-CoV-2 wild-type virus and pseudovirus neutralizing activity. Xcl1 also increased long-lived antibody-secreting plasma cells in bone marrow. These preliminary results indicate that Xcl1 serves as a molecular adjuvant for the SARS-CoV-2 vaccine and that our Xcl1-S fusion DNA vaccine is a potential COVID-19 vaccine candidate for use in further translational studies. MDPI 2022-03-08 /pmc/articles/PMC8951015/ /pubmed/35335039 http://dx.doi.org/10.3390/vaccines10030407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Qi, Hailong Sun, Zhongjie Yao, Yanling Chen, Ligong Su, Xuncheng Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title | Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title_full | Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title_fullStr | Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title_full_unstemmed | Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title_short | Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19 |
title_sort | immunogenicity of the xcl1-sars-cov-2 spike fusion dna vaccine for covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951015/ https://www.ncbi.nlm.nih.gov/pubmed/35335039 http://dx.doi.org/10.3390/vaccines10030407 |
work_keys_str_mv | AT qihailong immunogenicityofthexcl1sarscov2spikefusiondnavaccineforcovid19 AT sunzhongjie immunogenicityofthexcl1sarscov2spikefusiondnavaccineforcovid19 AT yaoyanling immunogenicityofthexcl1sarscov2spikefusiondnavaccineforcovid19 AT chenligong immunogenicityofthexcl1sarscov2spikefusiondnavaccineforcovid19 AT suxuncheng immunogenicityofthexcl1sarscov2spikefusiondnavaccineforcovid19 |